NVAX Stock Price, Analysis & Fundamentals

Analysis

Novavax, Inc. is a biotechnology company operating within the healthcare sector. The firm has a market capitalization of $1.18 billion and generates revenue of approximately $1.06 billion on an annual basis, employing 952 individuals. From a financial health perspective, Novavax reports a gross margin of 59.4%, operating margin of -112.7%, and profit margin of 32.1%. The company's return on assets stands at 18.0% while its current ratio is 2.27. In terms of liquidity, Novavax has cash reserves totaling $762.89 million but holds debt worth $251.14 million. The company's valuation metrics include a P/E ratio (TTM) of 3.55 and forward P/E of -24.84, with a price to book value of -7.52. Revenue growth over the past year has been negative at -16.6%, while earnings growth is not available for consideration.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Novavax, Inc.

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Visit website →

NVAX

Price History (1Y)

Analysis

About Novavax, Inc.

Key Statistics

Company Info